OncoMatch/Clinical Trials/NCT06444269
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
Is NCT06444269 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies microbubble CEUS Contrast Enhanced Ultrasound (CEUS) for breast cancer.
Treatment: microbubble CEUS Contrast Enhanced Ultrasound (CEUS) — 1\. Efficacy of PULSAR preoperative radiation 2. Evaluate potential of microbubble CEUS as an alternative to operative SLNBx 3. Evaluate potential of OA to evaluate treatment response of pre-operative radiation on the tumor
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative
Required: ESR1 positive
Required: PR (PGR) positive
Demographics
Prior therapy
Cannot have received: radiation therapy
Prior Radiation to the involved breast
Cannot have received: endocrine therapy
have not undergone surgery or neoadjuvant endocrine or chemotherapy for current breast cancer diagnosis
Cannot have received: chemotherapy
have not undergone surgery or neoadjuvant endocrine or chemotherapy for current breast cancer diagnosis
Cannot have received: surgery
have not undergone surgery or neoadjuvant endocrine or chemotherapy for current breast cancer diagnosis
Cannot have received: any therapy for ipsilateral breast cancer
Prior ipsilateral breast cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Southwestern Medical Center-Dallas · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06444269 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 positive is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR positive is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify